Alterity Therapeutics, a biotechnology company dedicated to developing treatments for neurodegenerative diseases, announced that their Chief Executive Officer, David Stamler, M.D., will be participating in the Sachs Associates 6th Annual Neuroscience Innovation Forum.

At the forum, Dr. Stamler will be featured on a panel, present a company update and participate in investor and business development meetings.

The forum will cover the latest developments in global bio-partnering and investment and scientific advances in key therapeutic areas of neurodegenerative diseases and CNS more broadly.

Alterity Therapeutics is based in Melbourne, Australia, and San Francisco, California, USA.